Comparing leukocyte-rich and leukocyte-poor platelet-rich plasma composition and matching formulation to tendinopathy vs intra-articular indications
Every platelet-rich plasma formulation — regardless of the commercial kit, device, or leukocyte content — begins with the same physical principle: centrifugal separation of whole blood by density. Understanding this shared starting point is essential to understanding why LR-PRP and LP-PRP are not two different drugs, but two different fractions carved out of the same centrifuge tube, separated by exactly where the operator draws the line between "plasma to keep" and "buffy coat to discard."
The PRP preparation process begins with a routine venous blood draw, typically 15–60mL depending on the target injection volume and specific commercial system used:
• Anticoagulant: blood is drawn directly into tubes pre-loaded with acid citrate dextrose solution A (ACD-A) or sodium citrate — both chelate ionized calcium, blocking the coagulation cascade at multiple points (calcium is a required cofactor for several clotting factors) without directly damaging platelets • Why not heparin or EDTA: heparin can activate platelets prematurely and interfere with subsequent growth factor release; EDTA over-chelates calcium and can distort platelet morphology, making ACD-A/citrate the preferred anticoagulants for orthobiologic PRP preparation • Autologous principle: because the blood is the patient's own, there is no risk of transmissible disease or immune/allergic reaction to the injectate itself — a major safety and regulatory advantage over allogeneic biologics • Point-of-care processing: unlike bone marrow or adipose tissue processing, essentially all PRP systems are simple enough to process chairside/office-side in 10–20 minutes using a small benchtop centrifuge, requiring no cell culture or laboratory infrastructure
When centrifuged, whole blood separates into three layers by density, exactly as in a standard complete blood count hematocrit spin:
1. Bottom layer — erythrocytes (red blood cells): the densest blood component (specific gravity ~1.09), packs to the bottom of the tube. This layer is discarded or minimized in all PRP preparations — RBCs contribute no useful growth factors and their lysis releases free hemoglobin/iron that may be locally irritating
2. Middle layer — the "buffy coat": a thin (typically 1–2mm), visually grayish-white band at the RBC/plasma interface, containing the platelet and leukocyte population (specific gravity ~1.06–1.08) — this is the layer of central biological interest
3. Top layer — plasma: the least dense component (specific gravity ~1.03), containing dissolved proteins, clotting factors, and a small residual platelet population; the platelet-poor plasma layer
The entire art and science of PRP kit design is in HOW MUCH of the buffy coat is captured, and at what point in that layer the aspiration needle or plunger stops: • Capturing more of the upper buffy coat (closer to the plasma interface): yields higher platelet concentration with relatively fewer leukocytes → tends toward LP-PRP • Capturing the full buffy coat depth (including material closer to the RBC interface): yields both high platelets AND high leukocyte carryover → LR-PRP
This single millimeter-scale aspiration decision is the entire mechanistic basis of the LR-PRP vs LP-PRP distinction — there is no different reagent or process, only a different depth of extraction from the same centrifuged tube.
Because the buffy coat is only 1–2mm thick, even small technical variations between operators, kits, or a single degree of tube tilt during aspiration can shift a nominal "LP-PRP" protocol toward unintentionally higher leukocyte content — a major source of inter-study and inter-clinic variability that complicates the orthobiologic evidence base (see the companion evidence-grade comparison simulation).
Commercial PRP systems are broadly divided into single-spin and double-spin (two-stage) protocols, and this single processing-protocol choice is the primary determinant of whether the final product is leukocyte-rich or leukocyte-poor. Understanding the mechanics of each protocol clarifies why "PRP" cannot be treated as a single, uniform biologic — it is a family of formulations with meaningfully different cellular content depending entirely on processing method.
Single-spin systems (e.g., many chairside kits marketed for sports medicine and orthopedic office use) perform one centrifugation cycle at relatively low relative centrifugal force (RCF), typically 200–400×g for 5–10 minutes:
• Mechanism: the soft spin is sufficient to separate red blood cells from plasma, but does not generate enough force or time to fully compact and separate the buffy coat leukocyte layer from the platelet-rich plasma layer above it • Result: the harvested "PRP" fraction inherently carries a substantial leukocyte population along with the concentrated platelets — by default, most single-spin kits produce LR-PRP unless the kit specifically incorporates a barrier gel or float designed to separate the buffy coat • Some single-spin systems use a density-separator gel (a thixotropic gel with a specific gravity between plasma and RBCs) that physically settles at the buffy-coat interface, allowing the RBC layer to be sequestered below the gel while a cleaner (though not leukocyte-free) plasma-platelet layer is aspirated above it — an intermediate approach • Advantages: faster processing (10–15 min total), simpler workflow, lower cost, single closed-system kit — favored in high-volume outpatient sports medicine clinics
2. Double-spin (two-stage) protocols: • First spin (soft, ~200×g): separates whole blood into RBC layer (bottom) and plasma + buffy coat (top), similar to the single-spin step • Intermediate step: the plasma + buffy coat supernatant is carefully transferred to a new tube, explicitly leaving the RBC layer behind • Second spin (hard, ~1000–1500×g): concentrates the platelets from this smaller volume into a tight pellet at the bottom of the second tube; the majority of the supernatant (now platelet-poor plasma) is removed • Selective resuspension: the technician can choose to resuspend the pellet by leaving behind (discarding) the leukocyte-dense uppermost portion of the pellet — producing a leukocyte-poor, highly platelet-concentrated final product • Advantages: higher platelet concentration factors achievable (often 5–8× baseline vs 3–5× for single-spin), and precise operator control over final leukocyte content — favored when LP-PRP is specifically desired for intra-articular use
Leukocyte-rich PRP retains neutrophils, monocytes, and lymphocytes at concentrations often several-fold above whole blood baseline, alongside the concentrated platelet population. This is not an unwanted contaminant to be minimized in every context — in chronic, hypovascular, degenerative tendon pathology, the pro-inflammatory and antimicrobial properties of these leukocytes are hypothesized to provide a therapeutic advantage by re-triggering a productive healing cascade in tissue that has stalled in a chronic, under-inflamed degenerative state.
The leukocyte population in LR-PRP is dominated by neutrophils (the most abundant circulating white cell), with lesser contributions from monocytes and lymphocytes. Upon activation, these cells release a distinct secretory profile:
• Reactive oxygen species (ROS): neutrophil respiratory burst releases superoxide, hydrogen peroxide, and hypochlorous acid — antimicrobial but also locally cytotoxic to surrounding cells at high concentration • Matrix metalloproteinases (MMP-8, MMP-9): neutrophil-derived proteases that degrade damaged/degenerated extracellular matrix collagen, theoretically clearing pathological tissue to make way for organized new matrix deposition • Pro-inflammatory cytokines: IL-1β, TNF-α, IL-6, and IL-8 recruit additional inflammatory cells to the injection site and upregulate local angiogenesis and fibroblast activity • Antimicrobial peptides: defensins and other neutrophil granule contents provide some theoretical antimicrobial benefit, occasionally cited (without strong direct clinical evidence) as a rationale in contaminated or high-infection-risk wound applications
The therapeutic rationale for tendinopathy specifically: chronic tendinopathy is now understood not as a straightforward inflammatory condition ("tendinitis") but as a failed, chronic degenerative healing response ("tendinosis") — characterized by disorganized collagen, increased ground substance, neovascularization, and a relatively hypocellular, hypovascular tissue environment. The theory behind LR-PRP is that reintroducing a controlled, time-limited inflammatory stimulus can "reset" this stalled healing cascade, triggering the same fibroblast recruitment and organized collagen remodeling seen in acute injury.
A frequently cited clinical trial supporting LR-PRP in tendinopathy: Gosens et al. (AJSM 2011) — a randomized trial of LR-PRP vs corticosteroid injection for chronic lateral epicondylitis showed LR-PRP produced superior, more durable symptom improvement at 1 and 2 years, while corticosteroid showed early superiority that reversed by 6 months — a pattern echoing the general durability trade-off seen between anti-inflammatory and regenerative injectables.
The rationale for tolerating (or favoring) leukocyte content in tendon applications, while avoiding it intra-articularly, rests on fundamental tissue biology differences:
• Tendon tissue: dense, fibrous, relatively hypovascular and hypocellular connective tissue with a slow baseline turnover rate; a localized, time-limited inflammatory stimulus is diluted across a smaller, more robust extracellular matrix and is less likely to have a systemic or diffuse catabolic effect on the entire structure • Synovial joint: an enclosed fluid compartment where any injected substance rapidly disperses through the synovial fluid and bathes the entire articular cartilage surface and synovial lining simultaneously — there is no localized containment, so a pro-inflammatory cytokine load affects the whole joint environment at once • Chondrocyte vulnerability: articular chondrocytes are exquisitely sensitive to IL-1β and TNF-α, which upregulate their own catabolic enzyme production (MMP-13, ADAMTS-5) and downregulate type II collagen and aggrecan synthesis — precisely the pathological process driving osteoarthritis progression • Net effect: what may be a beneficial, contained "wake-up" signal in tendon tissue may instead accelerate the very catabolic process that intra-articular orthobiologic therapy is meant to counteract
Leukocyte-poor PRP is processed specifically to minimize the neutrophil and monocyte population while preserving a high, concentrated platelet count. The theoretical advantage is delivering the beneficial α-granule growth factor payload of platelets — PDGF, TGF-β, VEGF, EGF, and IGF-1 — without the accompanying pro-inflammatory and catabolic cytokine burden that leukocytes contribute, an especially important consideration for the leukocyte-sensitive chondrocyte population of an osteoarthritic joint.
Regardless of leukocyte content, the platelets themselves are the shared active ingredient of all PRP formulations. Upon activation (by exposure to collagen, thrombin, or calcium chloride at the injection site), platelet α-granules degranulate and release a well-characterized suite of growth factors:
• Platelet-derived growth factor (PDGF-AA, AB, BB): stimulates fibroblast and mesenchymal cell proliferation and chemotaxis • Transforming growth factor-β (TGF-β1, β2): stimulates extracellular matrix synthesis (collagen, proteoglycan) and can also have context-dependent anti-inflammatory or pro-fibrotic effects • Vascular endothelial growth factor (VEGF): stimulates angiogenesis, important for restoring blood supply to hypovascular degenerative tissue • Epidermal growth factor (EGF): promotes epithelial and mesenchymal cell proliferation • Insulin-like growth factor-1 (IGF-1): promotes chondrocyte and osteoblast anabolic activity, proteoglycan synthesis • Fibroblast growth factor (FGF-2): promotes angiogenesis and fibroblast proliferation
Because LP-PRP retains a comparable (or even higher, in well-optimized double-spin protocols) platelet concentration factor to LR-PRP, it delivers essentially the same growth factor payload — the difference lies almost entirely in what else comes along with it.
A growing, increasingly well-stratified body of evidence supports LP-PRP as the preferred formulation for intra-articular knee OA injection, largely from meta-analyses that separately pool trials by leukocyte content rather than treating "PRP" as monolithic:
• Riboh et al. (AJSM 2016): systematic review and meta-analysis directly comparing LP-PRP, LR-PRP, and hyaluronic acid for knee OA — found LP-PRP produced significantly better WOMAC outcome scores than both LR-PRP and HA at final follow-up, while LR-PRP showed no significant advantage over HA • Chen et al. and subsequent network meta-analyses (2020–2022): consistently rank LP-PRP above LR-PRP for intra-articular OA on both pain and functional outcome measures • Proposed mechanism for the difference: in vitro chondrocyte co-culture studies show LR-PRP formulations induce significantly higher IL-1β and MMP-13 expression in cultured chondrocytes compared to LP-PRP at matched platelet concentration — directly linking leukocyte content to a measurable catabolic chondrocyte response • Clinical practice implication: this evidence has shifted contemporary sports medicine and orthopedic practice toward routinely specifying LP-PRP for intra-articular knee, hip, and shoulder injections, while continuing to favor LR-PRP (or accepting either) for extra-articular tendon and ligament applications
The Riboh et al. 2016 meta-analysis is frequently cited as the single most influential study reshaping PRP formulation selection practice — by demonstrating that pooling LR-PRP and LP-PRP trials together (as earlier meta-analyses had done) obscured a clinically meaningful difference, it retroactively explained why some earlier PRP-for-OA trials had shown disappointing or inconsistent results: they were often using LR-PRP in a joint environment where it may be actively counterproductive.
The accumulated mechanistic and clinical trial evidence now supports a tissue-specific formulation selection framework rather than a one-size-fits-all approach to PRP. This final stage synthesizes the biological rationale from the preceding stages into practical guidance — while acknowledging that reporting inconsistency across the PRP literature (many older trials do not specify leukocyte content at all) means this framework, while increasingly well-supported, is still an active area of refinement rather than settled dogma.
Synthesizing the mechanistic rationale and clinical trial evidence from the preceding stages, a working formulation-selection framework has emerged in contemporary orthobiologic practice:
Favor LR-PRP for: • Chronic tendinopathy (lateral/medial epicondylitis, patellar tendinopathy, Achilles tendinopathy) — hypovascular, degenerative tissue that may benefit from a controlled inflammatory "reset" stimulus • Chronic plantar fasciitis — similarly degenerative, hypovascular fascial tissue • Some muscle injury applications, where a robust early inflammatory/regenerative response is desired
Favor LP-PRP for: • Intra-articular knee, hip, and shoulder osteoarthritis — chondrocyte-sensitive, enclosed synovial fluid compartment where diffuse pro-inflammatory cytokine exposure is undesirable • Intra-articular injections generally, when the goal is cartilage-protective/anti-catabolic signaling rather than a remodeling stimulus • Applications in patients with a robust baseline inflammatory state (e.g., some inflammatory arthropathy overlap presentations), where added pro-inflammatory stimulus is more likely to be poorly tolerated
Context-dependent / less clear-cut: • Acute muscle strains: mixed evidence on which formulation is superior; timing of administration relative to injury phase may matter more than formulation • Rotator cuff tendinopathy with intra-articular component: anatomically ambiguous cases (e.g., partial-thickness tears near the joint) may require individualized judgment weighing both tissue targets
A recurring theme across the modern orthobiologic literature — and the central lesson of the LR-PRP/LP-PRP distinction — is that "PRP" is not a single standardized biologic product, but a broad category encompassing formulations that can differ by an order of magnitude in leukocyte content, several-fold in platelet concentration, and by activation method (calcium chloride, thrombin, or none/endogenous activation upon contact with tissue collagen).
The MIBO (Minimum Information for Studies Evaluating Biologics in Orthopaedics) checklist, increasingly adopted since approximately 2017–2018, requires trials to report: • Whole blood volume processed and final PRP volume • Platelet concentration (absolute count and fold-increase over baseline) • Leukocyte concentration and differential (neutrophil, monocyte, lymphocyte counts) • Red blood cell contamination level • Activation method (if any) and timing relative to injection • Single-spin vs double-spin processing protocol and specific commercial system/kit used
Retrospective analyses estimate that a substantial fraction (roughly 40%) of PRP trials published before this reporting standard became widespread failed to specify leukocyte content at all — meaning a meaningful portion of the historical "PRP for knee OA is inconclusive" literature likely included an uncharacterized mix of LR- and LP-PRP formulations, diluting any true formulation-specific effect. This is precisely the same "unstratified pooling" pitfall referenced in the evidence-grading literature for orthobiologics broadly.
The clinical and regulatory trajectory of PRP research illustrates a broader principle applicable across all orthobiologic modalities: as a field matures, precision in characterizing exactly what biologic product was studied — down to cellular composition, not just the product category name — becomes as important to generating reliable evidence as sample size or study design.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Leukocyte-Rich PRP (LR-PRP) | Neutrophils/monocytes 2–5× whole blood baseline; platelets 3–6× baseline | ROS, MMP-8/9, IL-1β/TNF-α/IL-6 alongside platelet growth factors — controlled inflammatory remodeling stimulus | Preferred for chronic tendinopathy (epicondylitis, patellar tendon) |
| Leukocyte-Poor PRP (LP-PRP) | Neutrophils/monocytes depleted >90%; platelets 4–6× baseline (often higher via double-spin) | PDGF, TGF-β, VEGF, EGF, IGF-1 delivered with minimal pro-inflammatory cytokine load | Preferred for intra-articular OA (knee, hip, shoulder) — chondrocyte-protective |
| Processing route | Single-spin (soft, ~200–400×g) → typically LR-PRP by default | Insufficient force/selectivity to exclude buffy coat leukocytes from harvested plasma | Faster, simpler, lower cost — favored for high-volume sports medicine clinics |
| Processing route | Double-spin (soft then hard, ~1000–1500×g) → typically LP-PRP | Second hard spin concentrates platelet pellet; operator selectively discards leukocyte-dense buffy coat | Higher platelet concentration factor; precise leukocyte-content control |